开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-08-13 ms6000000903004099 来自湖北省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了

71 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-09-19 ms1000001788820006 来自上海

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：24年3.26投稿
4.28修回意见，在这期间状态一直是under consideration
5.22上传修回稿，后面编辑让从新提交了几次
8月20接受。
整体感觉还可以，很庆幸。

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-07-19 Judy Bright 来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肺癌;肿瘤生物学
经验分享：今天刚刚接收一篇，分享一下投稿经历：

第一阶段：
Submission ---- 25th Jan 24
Under Consideration ---- 26th Jan 24
Decision Made ---- 9th Apr 24
收到一审意见 ---- 15th Apr 24

第二阶段：
Submission ---- 20th Jun 24
Under Consideration ---- 20th Jun 24
Decision Made ---- 15th Jul 24
Accepted in Principle ---- 19th Jul 24

497 33

展开33条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-06-28 Pig1000 来自重庆

偏重的研究方向：细胞死亡
经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大

127 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2023-07-13 ms7000000921712169 来自广东省

审稿速度:3.0 | 投稿命中率:25.0
偏重的研究方向：呼吸疾病
经验分享：刚刚中了一篇，比较顺利

184 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-09-11 148cbeecm22暂无昵称来自摩尔多瓦

请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗

7 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2023-04-27 122bcca1m71(暂无昵称) 来自上海

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：退行性疾病
经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。

156 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2023-08-21 姒尘来自浙江省

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：免疫学
经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦

92 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-05-23 123a6632m26暂无昵称来自辽宁省

已原则性接收，想问问正式接收还需要多久呀

100 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2219910, encodeId=c62b2219910d3, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：7月25号submit，7月25号under consideration，8月8号peer review，8月11号with editor，目前仍然是with editor，不清楚是什么情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4f065434476, createdName=ms6000000903004099, createdTime=Tue Aug 13 15:45:01 CST 2024, time=2024-08-13, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=497, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2212089, encodeId=1a2e2212089ec, content=偏重的研究方向：细胞死亡 经验分享：各位道友，这个杂志editor assigned一个多月正常吗？这种后面被不送外审直接拒的概率大不大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=Pig1000, createdTime=Fri Jun 28 13:17:26 CST 2024, time=2024-06-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0 偏重的研究方向：呼吸疾病 经验分享：刚刚中了一篇，比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2128641, encodeId=39ef21286417f, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：退行性疾病 经验分享：从CDD转头过来，2月初投稿，3月份送审，半个月意见修回，只有1个reveiwer的意见，小修把实验的数目加进去就可以了，拖着一直没投，4月中投回，次日退回，修了格式投回，第二天接收。担心是水刊。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=b1222355201, createdName=122bcca1m71(暂无昵称), createdTime=Thu Apr 27 12:34:17 CST 2023, time=2023-04-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2153892, encodeId=c1fa215389272, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：免疫学 经验分享：7月20日收到返修意见（第一段要求在2个月内修回，后续有个链接要求在8月18日前修回）按照要求在8月17日修回文章，文章于8月18日状态变为dicision made，这是什么情况呀。好担心是不是直接拒稿啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKBd8yotDymdRbFx61VexB4cMrmkZUogd5BjiaPxuxZGtCUkgT9kOicQAakgTZ6fWB8DKmia9yKXCiapw/132, createdBy=8e202546960, createdName=姒尘, createdTime=Mon Aug 21 16:50:39 CST 2023, time=2023-08-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2206199, encodeId=770622061998d, content=已原则性接收，想问问正式接收还需要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43d42425724, createdName=123a6632m26暂无昵称, createdTime=Thu May 23 15:09:03 CST 2024, time=2024-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2206322, encodeId=a2a522063227b, content=33天还是under consideration，心态崩了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Thu May 23 22:14:57 CST 2024, time=2024-05-23, status=1, ipAttribution=湖北省)]

2024-05-23 148cbeecm22暂无昵称来自湖北省

33天还是under consideration，心态崩了

60 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务